Anabol 4-19 History
Nordostebol acetate was first described in 1956. It was developed into a medicine by Piam, which sold it briefly decades ago under the trade name Anabol 4-19. The 4-19 referred to the unique structural modifications to the steroid, namely that it was a 4-chloro 19-nortestosterone (nandrolone) derivative. Like its cousin Megagrisevit (clostebol acetate), nordostebol acetate was manufactured in both oral and injectable forms. The drug was ultimately less successful than even Megagrisevit (which also was a poor performer internationally), probably because it was developed during a very competitive time in the industry, when many effective agents were vying for pharmacy dollars. Anabol 4-19 was abandoned by the manufacturer many years ago, and has been unavailable for so long that few athletes have any memory of it.
How is Anabol 4-19 Supplied
Nordostebol acetate is no longer available as a commercial agent.
Structural Characteristics of Anabol 4-19
Nordostebol is a modified form of nandrolone. It differs by the introduction of a hydroxyl group at carbon 4, which inhibits aromatization and reduces relative steroid androgenicity. Nordostebol acetate contains nordostebol modified with the addition of carboxylic acid ester (acetic acid) at the 17-beta hydroxyl group, so that the free steroid is released more slowly from the area of injection.
Anabol 4-19 Side Effects (Estrogenic)
Nordostebol is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when, using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, nordostebol instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns.
Anabol 4-19 Side Effects (Androgenic)
Although classified as an anabolic steroid, androgenic side effects are still possible with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Additionally, nordostebol is not extensively metabolized by the 5-alpha reductase enzyme, so its relative androgenicity is not greatly altered by the concurrent use of finasteride or dutasteride. Note that nordostebol is a steroid with relatively low androgenic activity relative to its tissue-building actions, making the threshold for strong androgenic side effects comparably higher than with more androgenic agents such as testosterone, methandrostenolone, or fluoxymesterone.
Anabol 4-19 Side Effects (Hepatotoxicity)
Norclostebol is not a cl 7-alpha alkylated compound, and not known to have hepatotoxic effects. Liver toxicity is unlikely.
Anabol 4-19 Side Effects (Cardiovascular)
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact ' of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Norclostebol should have a stronger negative effect on the hepatic management of cholesterol than testosterone or nandrolone due to its non-aromatizable nature, but a much weaker impact than c-17 alpha alkylated steroids. Anabolic/androgenic steroids may also adversely effect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, .all potentially increasing the risk of cardiovascular disease and myocardial infarction.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Anabol 4-19 Side Effects (Testosterone Suppression)
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
Anabol 4-19 Administration (Men)
Norclostebol acetate has been successfully used in clinical doses as low as 5-20 mg, which increased nitrogen retention for as long as 2 weeks. Effective doses for physique- or performance-enhancing purposes would fall in the range of 100-400 mg per week, taken for 6-12 weeks. Given the fast-acting nature of acetate injectables, the weekly dosage is generally subdivided into injections given at least every third day. An effective oral daily dosage falls in the range of 75-100 mg, although would be less cost-effective and produce stronger negative changes in blood lipids than the injectable. Cycles (oral or injectable) would generally last 6-12 weeks. Use of norclostebol acetate will not effect rapid mass gains, but is likely to produce slow but steady increases in strength and lean muscle tissue, with a concurrent increase in fat loss and muscle definition.
Anabol 4-19 Administration (Women)
Norclostebol acetate has been successfully used in clinical doses as low as 5-20 mg, which increased nitrogen retention for as long as 2 weeks. Effective doses for physique- or performance-enhancing purposes fall in the range of .50-75 mg per week for the injectable, or 25-50 mg daily for the oral, taken for no longer than 6 weeks. Note that virilizing side effects are still possible with use, and should be carefully monitored.
Anabol 4-19 Availability
Norclostebol acetate is no longer produced as a prescription agent.
Wlliam Llewellyn (2017) - Anabolics